Recent Updates
Recently added Catalysts
XENE Positive Sentiment Score: 75/100

Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Key Takeaway: Xenon Pharmaceuticals Inc. has announced its participation at the Goldman Sachs 46th Annual Global Healthcare Conference, scheduled for June 9-11, 2025, in Miami, FL. Ian Mortimer, the company's CEO, will present on June 10, 2025, at 3:20 PM Eastern Time. The presentation will be available through a live audio webcast on the company's website, which will also be accessible for replay afterward. Xenon focuses on neuroscience therapies and is advancing its product portfolio with a particular emphasis on treatments for epilepsy and depression.

Market Sentiment Analysis

POSITIVE FACTORS

  • Xenon Pharmaceuticals is participating in a prestigious healthcare conference.
  • The company's focus on developing therapeutics for high unmet medical needs is commendable.
  • Azetukalner shows promise as a leading candidate in late-stage clinical development.

Full Press Release Details

VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference taking place in Miami, FL, from June 9-11, 2025.
Fireside Chat Presentation Details:
Date : Tuesday, June 10, 2025
Time : 3:20-3:55 PM Eastern Time
Webcast : Register here
Presenter : Ian Mortimer, President and Chief Executive Officer
A live audio webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Vice President, Investor Relations
Senior Vice President, Corporate Affairs

Frequently Asked Questions

When will Xenon Pharmaceuticals present at the Goldman Sachs conference?

Xenon Pharmaceuticals will present on June 10, 2025, from 3:20-3:55 PM ET.

Who will present on behalf of Xenon Pharmaceuticals?

Ian Mortimer, President and CEO, will be the presenter for Xenon Pharmaceuticals.

Where can I watch the Xenon Pharmaceuticals presentation?

The presentation will be available on Xenon's website under the 'Investors' section.

What is Xenon Pharmaceuticals known for?

Xenon Pharmaceuticals focuses on developing therapeutics for epilepsy and depression.

What is Azetukalner?

Azetukalner is a selective Kv7 potassium channel opener in late-stage clinical development.

Last updated: Jun 3, 2025